Published in Aust N Z J Psychiatry on December 01, 2009
Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry (2014) 1.14
Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol (2012) 0.82
Cannabis use and cognitive dysfunction. Indian J Psychiatry (2011) 0.75
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry (2010) 3.88
Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res (2013) 3.01
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res (2006) 1.66
Suicide risk in placebo-controlled trials of treatment for acute manic episode and prevention of manic-depressive episode. Am J Psychiatry (2005) 1.52
Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res (2010) 1.52
Deep brain stimulation restores frontostriatal network activity in obsessive-compulsive disorder. Nat Neurosci (2013) 1.45
Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr Res (2009) 1.43
Diffusion tensor imaging in the early phase of schizophrenia: what have we learned? J Psychiatr Res (2010) 1.32
Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull (2012) 1.22
Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psychiatr Res (2012) 1.21
The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions. Schizophr Res (2006) 1.18
Whither the attenuated psychosis syndrome? Schizophr Bull (2012) 1.12
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
Disability in people clinically at high risk of psychosis. Br J Psychiatry (2010) 1.10
Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. Schizophr Res (2011) 1.10
Attitudes of patients toward the first psychotic episode and the start of treatment. Schizophr Bull (2002) 1.09
Risperidone-induced leucopenia and neutropenia: a case report. Eur Psychiatry (2004) 1.07
Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings. Behav Brain Funct (2007) 1.06
Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab (2007) 1.06
Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res (2012) 1.05
The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population. Schizophr Bull (2012) 1.05
Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries. Schizophr Res (2012) 1.04
White matter fibertracking in first-episode schizophrenia, schizoaffective patients and subjects at ultra-high risk of psychosis. Neuropsychobiology (2008) 1.02
Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res (2011) 1.02
Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry (2010) 1.00
The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. Schizophr Bull (2011) 0.98
White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. Schizophr Res (2011) 0.94
Antisaccade task performance in patients at ultra high risk for developing psychosis. Schizophr Res (2007) 0.94
New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. Int J Epidemiol (2015) 0.93
Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. Aust N Z J Psychiatry (2010) 0.93
Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness. Schizophr Bull (2010) 0.92
AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur J Nucl Med Mol Imaging (2008) 0.91
Pericardial and bilateral pleural effusion associated with clozapine treatment. Eur Psychiatry (2004) 0.90
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry (2002) 0.90
Off-label second generation antipsychotics for impulse regulation disorders: a review. Psychopharmacol Bull (2010) 0.88
Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis. Schizophr Bull (2012) 0.88
Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. Biol Psychiatry (2010) 0.88
A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. Biol Psychiatry (2013) 0.87
Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacol Bull (2006) 0.87
White matter connectivity and psychosis in ultra-high-risk subjects: a diffusion tensor fiber tracking study. Psychiatry Res (2010) 0.86
The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. Schizophr Bull (2013) 0.86
Schizophrenia spectrum disorders in later life: prevalence and distribution of age at onset and sex in a dutch catchment area. Am J Geriatr Psychiatry (2012) 0.86
Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophr Bull (2003) 0.86
Adult attachment and psychotic phenomenology in clinical and non-clinical samples: a systematic review. Psychol Psychother (2013) 0.86
Pathways to psychosis: help-seeking behavior in the prodromal phase. Schizophr Res (2011) 0.85
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. J Clin Psychiatry (2011) 0.85
Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Res (2013) 0.85
Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. PLoS One (2011) 0.85
Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology (2009) 0.85
The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacol Bull (2008) 0.85
Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur Neuropsychopharmacol (2006) 0.85
Obsessive-compulsive symptoms in first episode psychosis and in subjects at ultra high risk for developing psychosis; onset and relationship to psychotic symptoms. Aust N Z J Psychiatry (2010) 0.85
Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Curr Pharm Des (2012) 0.85
Reduced context effects on retrieval in first-episode schizophrenia. PLoS One (2010) 0.84
Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic- and pre-psychotic symptoms. Aust N Z J Psychiatry (2010) 0.84
Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity? Psychopharmacol Bull (2009) 0.84
Cognitive impairment in late life schizophrenia and bipolar I disorder. Int J Geriatr Psychiatry (2012) 0.84
Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar Disord (2013) 0.84
Factor analysis of the scale of prodromal symptoms: differentiating between negative and depression symptoms. Psychopathology (2011) 0.84
Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. Int Clin Psychopharmacol (2009) 0.84
Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. Neuropsychopharmacology (2007) 0.84
Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Hum Psychopharmacol (2008) 0.84
The course of parental expressed emotion and psychotic episodes after family intervention in recent-onset schizophrenia. A longitudinal study. Schizophr Res (2002) 0.84
Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients. PLoS One (2012) 0.84
Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacol Bull (2008) 0.84
Psychosocial outcome in patients at clinical high risk of psychosis: a prospective follow-up. Soc Psychiatry Psychiatr Epidemiol (2012) 0.84
Relationship between working-memory network function and substance use: a 3-year longitudinal fMRI study in heavy cannabis users and controls. Addict Biol (2013) 0.83
Dopaminergic modulation of the human reward system: a placebo-controlled dopamine depletion fMRI study. J Psychopharmacol (2010) 0.83
Social functioning among older community-dwelling patients with schizophrenia: a review. Am J Geriatr Psychiatry (2010) 0.83
Subjective experiences during dopamine depletion. Am J Psychiatry (2005) 0.83
The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val¹⁵⁸Met polymorphism. Schizophr Res (2013) 0.83
Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics (2005) 0.83
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can J Psychiatry (2008) 0.82
Auditory ERP components before and after transition to a first psychotic episode. Biol Psychol (2011) 0.82
History of trauma and the association with baseline symptoms in an Ultra-High Risk for psychosis cohort. Psychiatry Res (2013) 0.82
Transition to first episode psychosis in ultra high risk populations: does baseline functioning hold the key? Schizophr Res (2012) 0.82